Novo Nordisk A/S (ETR:NOV)
Germany · Delayed Price · Currency is EUR 42.39
+0.70 (1.69%)
At close: Nov 28, 2025
Novo Nordisk Employees
As of December 31, 2024, Novo Nordisk had 77,349 total employees, including 76,302 full-time and 1,047 part-time employees. The number of employees increased by 13,030 or 20.26% compared to the previous year.
Employees
77,349
Change (1Y)
13,030
Growth (1Y)
20.26%
Revenue / Employee
€537,940
Profits / Employee
€176,879
Market Cap
188.60B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 77,349 | 13,030 | 20.26% |
| Dec 31, 2023 | 64,319 | 9,134 | 16.55% |
| Dec 31, 2022 | 55,185 | 6,707 | 13.84% |
| Dec 31, 2021 | 48,478 | 3,155 | 6.96% |
| Dec 31, 2020 | 45,323 | 2,065 | 4.77% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fresenius SE & Co. KGaA | 176,486 |
| Fresenius Medical Care AG | 111,513 |
| Bayer Aktiengesellschaft | 91,864 |
| Siemens Healthineers AG | 73,840 |
| Merck KGaA | 59,020 |
| Fielmann Group AG | 24,363 |
| Sartorius Aktiengesellschaft | 13,528 |
| Carl Zeiss Meditec AG | 5,730 |
Novo Nordisk News
- 1 day ago - Why Novo Nordisk Stock Just Hit a 4-Year Low - The Motley Fool
- 2 days ago - Novo Nordisk: Headwinds On The Surface, Deep Value If You Dig - Seeking Alpha
- 2 days ago - Novo Nordisk: A Textbook Value Trap - Seeking Alpha
- 2 days ago - Novo Nordisk Stock Investors Get Huge News on Drug Trial Results - The Motley Fool
- 4 days ago - How Medicare's new drug prices could reshape Novo Nordisk and european pharma - Invezz
- 4 days ago - Why Novo Nordisk Stock Is Moving Higher Today - The Motley Fool
- 4 days ago - Novo Nordisk Wants FDA Nod For A Higher-Dose Wegovy - Benzinga
- 4 days ago - Why Medicare price negotiations matter for Novo Nordisk, AstraZeneca, and other European pharma companies - CNBC